| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 1 | +0.00% | +64.72% | +1.08% | +63.64% | +63.64% | — |
| 14d | 1 | +0.00% | +69.72% | -1.47% | +71.20% | +71.20% | — |
| 30d | 1 | +0.00% | +35.63% | -0.22% | +35.85% | +35.85% | — |
| 60d | 1 | +0.00% | +23.61% | -2.23% | +25.84% | +25.84% | — |
| 90d | 1 | +0.00% | +17.57% | -4.19% | +21.76% | +21.76% | — |
| 180d | 1 | +0.00% | +68.13% | +8.30% | +59.83% | +59.83% | — |
| 1y | 1(1 pending) | — | — | — | — | — | — |
| 2y | 1(1 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASE Chief Scientific Officer | 3,000 | $6.14 | $18.4K | 70,845 | Jun 23, 2026 | Jun 25, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 3,000 | $20.00 | $60.0K | 67,845 | Jun 23, 2026 | Jun 25, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Scientific Officer | 3,000 | — | — | 203,290 | Jun 23, 2026 | Jun 25, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 3,000 | $19.00 | $57.0K | 67,845 | Jun 17, 2026 | Jun 18, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Scientific Officer | 3,000 | — | — | 206,290 | Jun 17, 2026 | Jun 18, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASE Chief Scientific Officer | 3,000 | $6.14 | $18.4K | 70,845 | Jun 17, 2026 | Jun 18, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASE Chief Scientific Officer | 6,000 | $6.14 | $36.8K | 73,845 | May 29, 2026 | Jun 1, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 6,000 | $19.87 | $119.2K | 67,845 | May 29, 2026 | Jun 1, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Scientific Officer | 6,000 | — | — | 209,290 | May 29, 2026 | Jun 1, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Scientific Officer | 3,155 | $15.17 | $47.9K | 67,845 | Jan 5, 2026 | Jan 5, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 35,000 | — | — | 71,000 | Jan 2, 2026 | Jan 5, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 158,000 | — | — | 158,000 | Jan 2, 2026 | Jan 5, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 161,000 | — | — | 161,000 | Jan 2, 2025 | Jan 6, 2025 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 36,000 | — | — | 36,000 | Jan 2, 2025 | Jan 6, 2025 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 40,000 | — | — | 40,000 | Jun 3, 2024 | Jun 5, 2024 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 78,550 | — | — | 78,550 | Jan 3, 2023 | Jan 4, 2023 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 70,000 | — | — | 70,000 | Mar 1, 2022 | Mar 2, 2022 ↗ | View → |